# PROJECT STATUS SUMMARY - mcPhases Glucose Analysis
## Quick Reference for Submission Preparation

---

## ✅ COMPLETED COMPONENTS

### Data Processing & Feature Engineering
- ✅ Glucose unit conversion (mg/dL → mmol/L)
- ✅ Daily aggregation of 5-minute CGM readings
- ✅ Glucose metrics calculation: CV, TIR, MAGE, postprandial AUC, overnight basal
- ✅ HRV feature extraction: RMSSD, LF/HF ratio, coverage
- ✅ BMI calculation and categorization
- ✅ Feature engineering: BMI derivatives, HRV interactions, participant baselines
- ✅ One-hot encoding for categorical variables
- ✅ Median imputation strategy
- ✅ StandardScaler implementation

### Model Development
- ✅ Random Forest Regressor implemented
- ✅ Gradient Boosting Regressor implemented  
- ✅ Ridge Regression implemented
- ✅ Custom model wrapper classes (GlucosePredictionModel)
- ✅ Feature importance extraction
- ✅ Basic train/test split

### Visualizations
- ✅ BMI distribution plots
- ✅ HRV distribution plots
- ✅ Actual vs. Predicted scatter plots
- ✅ Residual plots
- ✅ Feature importance bar charts
- ✅ Model performance comparison charts

### Documentation
- ✅ Comprehensive glucose metrics library (GlucoseMetricsCalculator)
- ✅ Modular code structure (AI_Period_Tracker_LLM/)
- ✅ Copilot instructions for AI agents
- ✅ Interactive Jupyter notebooks

---

## ❌ CRITICAL GAPS (Blocking Valid Results)

### Data Quality Issues
- ❌ **BMI-HRV data alignment:** Only 0→10 valid merged records
- ❌ **40% missing BMI data:** Severe selection bias
- ❌ **100% missing PDG (progesterone):** Cannot model hormonal effects
- ❌ **Synthetic test data:** Current results on 10 fabricated samples

### Statistical Validity
- ❌ **Random train/test split:** Leaks future information (invalid for time-series)
- ❌ **No cross-validation:** Single split, no variance estimates
- ❌ **No hyperparameter tuning:** Using default parameters
- ❌ **Severe overfitting:** Train R²=0.87, Test R²=0.25

### Missing Features
- ❌ **No lagged glucose features:** Prior days' values not included
- ❌ **No sleep data integration:** Sleep duration/quality unused
- ❌ **No activity data integration:** Steps, calories, exercise unused
- ❌ **No time-of-day features:** Circadian patterns ignored
- ❌ **No hormonal predictors:** LH, estrogen not in model

### Clinical Validation
- ❌ **No Clarke Error Grid:** Cannot assess clinical accuracy
- ❌ **No MAPE calculation:** Missing percentage error metric
- ❌ **No time-lag analysis:** Don't know prediction horizon
- ❌ **No prospective validation:** Retrospective only

### Fairness & Generalizability
- ❌ **Unknown demographics:** Age, race, ethnicity not analyzed
- ❌ **No subgroup analysis:** Performance by BMI category, etc.
- ❌ **No bias audit:** Algorithmic fairness not assessed
- ❌ **Single-device dependence:** Fitbit+Dexcom only

---

## ⚠️ PARTIAL IMPLEMENTATIONS

### Partially Complete
- ⚠️ **Menstrual phase analysis:** Descriptive stats done, formal tests pending
- ⚠️ **Feature selection:** Domain knowledge used, formal methods pending
- ⚠️ **Model evaluation:** Basic metrics done, clinical metrics pending
- ⚠️ **Time-series processing:** Daily aggregation done, lagged features pending

---

## 🎯 IMMEDIATE PRIORITIES (Next 7 Days)

### Priority 1: Fix Data Foundation (Days 1-2)
```
[ ] Debug BMI-HRV participant ID mismatches
[ ] Create properly aligned dataset with real data
[ ] Verify >100 valid observations for training
[ ] Document data quality metrics
```

### Priority 2: Implement Valid Train/Test Split (Day 3)
```
[ ] Temporal split (first 80% days → train, last 20% → test)
[ ] OR: Leave-one-participant-out cross-validation
[ ] Verify no future information leakage
[ ] Document split strategy in methods
```

### Priority 3: Cross-Validation & Tuning (Days 4-5)
```
[ ] Implement TimeSeriesSplit (5 folds)
[ ] GridSearchCV for hyperparameter tuning
[ ] Calculate confidence intervals for metrics
[ ] Identify best model + parameters
```

### Priority 4: Clinical Metrics (Days 6-7)
```
[ ] Implement Clarke Error Grid Analysis
[ ] Calculate MAPE for all targets
[ ] Time-lag analysis (1hr, 4hr, 24hr predictions)
[ ] Generate clinical validation plots
```

---

## 📊 RECOMMENDED TIMELINE TO SUBMISSION

### Week 1: Core Model Validation
**Goal:** Valid train/test results on real data

- **Days 1-2:** Fix data alignment issue
- **Day 3:** Implement temporal train/test split
- **Days 4-5:** Cross-validation + hyperparameter tuning
- **Days 6-7:** Basic clinical metrics (Clarke Grid, MAPE)

**Deliverable:** Valid R², RMSE, MAE, MAPE on properly split test set

### Week 2: Feature Engineering & Advanced Models
**Goal:** Improve model performance with richer features

- **Days 8-10:** Add lagged features (prior days' glucose)
- **Days 11-12:** Integrate sleep + activity Fitbit data
- **Days 13-14:** Train XGBoost, LightGBM, or LSTM models

**Deliverable:** Improved test R² (target >0.5), feature importance analysis

### Week 3: Clinical Validation & Fairness Analysis
**Goal:** Ensure clinical relevance and algorithmic fairness

- **Days 15-16:** Complete Clarke Error Grid with Zone A+B percentage
- **Days 17-18:** SHAP value analysis for interpretability
- **Days 19-20:** Demographic subgroup analysis (if data available)
- **Day 21:** Generate all required visualizations

**Deliverable:** Clinical validation report, fairness audit

### Week 4: Manuscript Preparation
**Goal:** Submission-ready paper

- **Days 22-23:** Write Methods section (use TECHNICAL_SUBMISSION_ANSWERS.md)
- **Days 24-25:** Write Results section (tables + figures)
- **Day 26:** Write Discussion + Limitations
- **Days 27-28:** Peer review + final edits

**Deliverable:** Complete manuscript ready for submission

---

## 📈 PERFORMANCE TARGETS

### Minimum Acceptable Performance (for submission)
- **R² ≥ 0.4** on test set (explains 40% of variance)
- **Clarke Error Grid: ≥80% in Zones A+B** (clinically acceptable)
- **RMSE < 15%** of target mean for each glucose metric
- **Cross-validation std < 0.1** (stable across folds)

### Publication-Quality Performance (stretch goals)
- **R² ≥ 0.6** on test set
- **Clarke Error Grid: ≥95% in Zones A+B** (clinical deployment standard)
- **RMSE < 10%** of target mean
- **Subgroup R² within ±0.1** of overall (fairness)

---

## 🚨 SHOWSTOPPERS (Do NOT Submit If Present)

1. ❌ **Test set <50 samples:** Insufficient for statistical validity
2. ❌ **Random train/test split on time-series data:** Methodologically invalid
3. ❌ **No cross-validation:** Cannot assess model stability
4. ❌ **R² < 0.2:** Model has no predictive power
5. ❌ **No clinical validation metrics:** Cannot claim healthcare relevance
6. ❌ **Synthetic/fabricated test data:** Scientific misconduct

**Current Status: 4/6 showstoppers present → DO NOT SUBMIT**

---

## ✅ CHECKLIST FOR SUBMISSION READINESS

### Data Quality
- [ ] ≥100 valid participant-days in test set
- [ ] <20% missing data per feature (or documented imputation)
- [ ] Real data (not synthetic/simulated)
- [ ] Data alignment verified (participant IDs match across datasets)

### Model Validation
- [ ] Temporal or participant-based train/test split
- [ ] Cross-validation with ≥5 folds
- [ ] Hyperparameter tuning documented
- [ ] Test R² ≥ 0.4 for at least one target

### Clinical Metrics
- [ ] Clarke Error Grid implemented and visualized
- [ ] MAPE calculated for all targets
- [ ] Time-lag analysis (predict N hours ahead)
- [ ] ≥80% predictions in Clarke Zones A+B

### Visualizations
- [ ] Actual vs. Predicted scatter plots (all targets)
- [ ] Time-series predictions for ≥3 sample participants
- [ ] Residual plots showing homoscedasticity
- [ ] Feature importance analysis with interpretations
- [ ] Clarke Error Grid plot

### Documentation
- [ ] Methods section written (see TECHNICAL_SUBMISSION_ANSWERS.md)
- [ ] Results tables formatted (model comparison, metrics)
- [ ] Discussion addresses limitations honestly
- [ ] Acknowledgment of no prospective validation
- [ ] Fairness concerns documented

### Ethical Considerations
- [ ] Demographic bias analysis (if data available)
- [ ] Limitations section includes fairness concerns
- [ ] No claims of clinical deployment readiness
- [ ] Prospective validation recommended as next step

---

## 🎓 KEY MESSAGES FOR PAPER

### What We CAN Claim:
✅ "Proof-of-concept that wearable physiological data can predict glucose regulation metrics"
✅ "Preliminary evidence that HRV and BMI are associated with glucose variability"
✅ "Framework for future prospective validation studies"
✅ "Novel composite glucose regulation score (Cremaster Score)"

### What We CANNOT Claim:
❌ "Clinically validated predictive model"
❌ "Ready for deployment in healthcare settings"
❌ "Generalizable to all populations"
❌ "Superior to existing clinical assessments (HbA1c, OGTT)"

### Required Caveats:
⚠️ "Results require prospective validation in diverse populations"
⚠️ "Model trained on small sample (N=42) of menstruating women"
⚠️ "Unknown demographic composition limits generalizability"
⚠️ "Algorithmic fairness across subgroups not yet assessed"
⚠️ "No comparison to standard-of-care diabetes screening methods"

---

## 📞 NEXT STEPS - ACTION ITEMS

### Today (Day 1):
1. Review TECHNICAL_SUBMISSION_ANSWERS.md thoroughly
2. Discuss with team: Are we submitting in 1 week, 2 weeks, or 4 weeks?
3. Prioritize gaps based on submission timeline
4. Assign tasks if working collaboratively

### This Week:
1. Fix data alignment issue (highest priority)
2. Re-run models on real, properly aligned data
3. Implement temporal train/test split
4. Document current performance honestly

### Decision Point (End of Week 1):
**IF** test R² ≥ 0.4 and Clarke Grid ≥80% in A+B:
   → Proceed to Week 2 (feature engineering)

**IF** test R² < 0.4 or data issues persist:
   → Pivot to descriptive analysis paper (no predictive modeling claims)
   → Focus on menstrual phase effects on glucose patterns
   → Report associations, not predictions

---

## 📚 REFERENCES FOR METHODS SECTION

**Glucose Metrics:**
- Kovatchev et al. (2003) - Clarke Error Grid original paper
- Danne et al. (2017) - International consensus on CGM metrics
- Rodbard (2009) - Interpretation of continuous glucose monitoring data

**HRV & Metabolism:**
- Thayer et al. (2010) - Heart rate variability, prefrontal neural function, and cognitive performance
- Carnethon et al. (2003) - Prospective investigation of ANS function and diabetes

**Machine Learning for Glucose:**
- Woldaregay et al. (2019) - Data-driven blood glucose pattern classification and anomalies detection
- Dave et al. (2021) - Feature-based machine learning model for real-time hypoglycemia prediction

**Fairness in Healthcare AI:**
- Obermeyer et al. (2019) - Dissecting racial bias in an algorithm used to manage health
- Gichoya et al. (2022) - AI recognition of patient race in medical imaging

---

## 💡 ALTERNATIVE SUBMISSION STRATEGIES

### Option A: Full Predictive Modeling Paper (4 weeks)
**Focus:** "Machine Learning Prediction of Glucose Regulation from Wearable Data"
**Requirements:** All critical gaps addressed, R² ≥0.4, clinical validation
**Timeline:** 4 weeks (see Week 1-4 breakdown above)

### Option B: Descriptive Analysis Paper (1-2 weeks)
**Focus:** "Menstrual Cycle Phase Effects on Glucose Regulation Patterns"
**Requirements:** Statistical tests (ANOVA), phase-stratified glucose metrics, visualizations
**Timeline:** 1-2 weeks (less feature engineering needed)
**Advantage:** Sidesteps overfitting issues, focuses on novel biological findings

### Option C: Methods/Tool Paper (2 weeks)
**Focus:** "Cremaster Score: A Composite Metric for Glucose Regulation from CGM Data"
**Requirements:** Score validation, correlation with HbA1c (if available), reproducibility
**Timeline:** 2 weeks
**Advantage:** Contributes new measurement tool, less ML rigor needed

### RECOMMENDATION: 
Given current state, **Option B (Descriptive Analysis)** is safest for 1-week deadline.
**Option A (Full ML Paper)** is achievable with 4-week timeline and dedicated effort.

---

**Document Created:** November 7, 2025
**Status:** Draft for internal team discussion
**Next Review:** After Week 1 data alignment fix
